A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

NCT03993132 · clinicaltrials.gov ↗

COMPLETED

Status

26774

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Empagliflozin
DRUG: Liraglutide

Sponsor

Boehringer Ingelheim